{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:28:30Z","timestamp":1786728510390,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/0973-1482.206865","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T07:43:49Z","timestamp":1495525429000},"page":"550-555","source":"Crossref","is-referenced-by-count":3,"title":["Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma?"],"prefix":"10.4103","volume":"15","author":[{"given":"Asude","family":"Aksoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emin Tamer","family":"Elkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Harputluoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adile Ferda","family":"Dagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Isikdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhat","family":"Urakci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-17-20230619","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: The role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R3-17-20230619","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/107327480301000404","article-title":"Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer","volume":"10","author":"Rosell","year":"2003","journal-title":"Cancer Control"},{"key":"R4-17-20230619","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R5-17-20230619","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.lungcan.2008.09.002","article-title":"Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel","volume":"64","author":"Azuma","year":"2009","journal-title":"Lung Cancer"},{"key":"R6-17-20230619","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/1097-0142(19930415)71:8<2689::AID-CNCR2820710843>3.0.CO;2-H","article-title":"The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition","volume":"71","author":"Shanmugaratnam","year":"1993","journal-title":"Cancer"},{"key":"R7-17-20230619","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann Oncol"},{"key":"R8-17-20230619","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","article-title":"ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy","volume":"19","author":"Shirota","year":"2001","journal-title":"J Clin Oncol"},{"key":"R9-17-20230619","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.oraloncology.2012.04.003","article-title":"Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy","volume":"48","author":"Huang","year":"2012","journal-title":"Oral Oncol"},{"key":"R10-17-20230619","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.ijrobp.2008.05.023","article-title":"Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors","volume":"73","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R11-17-20230619","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.oraloncology.2011.11.017","article-title":"The prognostic value of histological typing in nasopharyngeal carcinoma","volume":"48","author":"Cheung","year":"2012","journal-title":"Oral Oncol"},{"key":"R12-17-20230619","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1200\/JCO.2004.00.7542","article-title":"Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group","volume":"23","author":"Lee","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-17-20230619","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ijrobp.2009.12.072","article-title":"Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?","volume":"79","author":"Chan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-17-20230619","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1158\/1078-0432.CCR-07-0252","article-title":"Excision repair cross complementation group1 immuno-histochemical expression predicts objective response and cancer-specific survival in patients treadet by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma","volume":"13","author":"Handra-Luca","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R15-17-20230619","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3892\/or.2011.1133","article-title":"ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation","volume":"25","author":"De Castro","year":"2011","journal-title":"Oncol Rep"},{"key":"R16-17-20230619","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/annonc\/mdp002","article-title":"Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma","volume":"20","author":"Koh","year":"2009","journal-title":"Ann Oncol"},{"key":"R17-17-20230619","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2006.09.7915","article-title":"Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer","volume":"25","author":"Cobo","year":"2007","journal-title":"J Clin Oncol"},{"key":"R18-17-20230619","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/B:BIGI.0000043957.03420.7e","article-title":"No association between base excision repair gene polymorphisms and risk of lung cancer","volume":"42","author":"Vogel","year":"2004","journal-title":"Biochem Genet"},{"key":"R19-17-20230619","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-04-2216","article-title":"ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin\/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer","volume":"11","author":"Viguier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R20-17-20230619","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/annonc\/mdp065","article-title":"Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma \u2013 Correlation with excision repair cross-complementing-1 polymorphisms","volume":"20","author":"Ma","year":"2009","journal-title":"Ann Oncol"},{"key":"R21-17-20230619","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2559.2011.04062.x","article-title":"DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: Analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors","volume":"60","author":"Lima","year":"2012","journal-title":"Histopathology"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201915030-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:28:01Z","timestamp":1786724881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201915030-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.206865","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}